4-piperazinylindole derivatives with 5-HT6 receptor affinity

Details 4-piperazinylindole derivatives with 5-HT6 receptor affinity 4-piperazinylindole derivatives with 5-HT6 receptor affinity

2002-06-14

2004-09-14

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S373000

Reexamination Certificate

active

06790848

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to new 4-piperazinyl indole derivatives with 5-HT6 receptor affinity, and associated pharmaceutical compositions, methods for use as therapeutic agents, and methods of preparation thereof.
BACKGROUND OF THE INVENTION
The actions of the neurotransmitter 5-hydroxytryptamine (5-HT) as a major modulatory neurotransmitter in the brain, are mediated through a number of receptor families termed 5-HT1, 5-HT2, 5- HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7. Based on a high level of 5-HT6 receptor mRNA in the brain, it has been stated that the 5-HT6 receptor may play a role in the pathology and treatment of central nervous system disorders. In particular, 5-HT6 receptor selective ligands have been identified as potentially useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, migraine, Alzheimer's disease (enhancement of cognitive memory), sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Such compounds are also expected to be of use in the treatment of certain gastrointestinal (GI) disorders such as functional bowel disorder. (See for ex. B. L. Roth et al., J. Pharmacol. Exp. Ther., 268, pages 1403-14120 (1994), D. R. Sibley et al., Mol. Pharmacol., 43, 320-327 (1993), A. J. Sleight et al, Neurotransmission, 11, 1-5 (1995), and A. J. Sleight et al. Serotonin ID Research Alert, 1997, 2 (3), 115-8).
Furthermore, the effect of 5-HT6 antagonist and 5-HT6 antisense oligonucleotides to reduce food intake in rats has been reported (Br J Pharmac. 1999 Suppl 126, page 66 and J Psychopharmacol Suppl A64 1997, page 255).
SUMMARY OF THE INVENTION
This invention relates to compounds comprising Formula I:
wherein:
R
1
is selected from hydrogen, halo, haloalkyl, and C
1-6
-alkyl;
R
2
is selected from hydrogen, C
1-6
-alkyl, C
1-6
-alkoxy, and C
1-6
-alkylthio;
R
3
is —SO
2
—Ar, and Ar is selected from aryl and heteroaryl, optionally substituted with one or more substitutents selected from lower alkyl, lower alkoxy, thioalkyl, halo, haloalkyl, hydroxyalkyl, nitro, hydroxy, cyano, amino, alkylamino, dialkylamino, aminocarbonyl, carbonylamino, alkylsulfonyl, haloalkylsulfonyl, aminosulfonyl, and sulfonylamino;
R
4
is selected from hydrogen, halogen, C
1-6
-alkyl, C
1-6
-alkoxy, C
1-6
-alkylthio, trifluoromethyl, cyano, and acyl; and
R
5
is selected from hydrogen, C
1-6
-alkyl and benzyl; or individual isomers, racemic or non racemic mixtures of isomers, prodrugs, or pharmaceutically acceptable salts or solvates thereof.
In another aspect, the invention relates to pharmaceutical compositions containing a therapeutically effective amount of at least one compound of Formula I, or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof, in admixture with at least one suitable carrier.
In another aspect, this invention relates to a method of treatment of a disease in a mammal treatable by administration of compound of Formula I having a selective affinity to 5-HT6 receptor, in particular a method of treatment in a subject having a disease state comprising Alzheimer's disease, central nervous disorders, such as for example, psychoses, schizophrenia, manic depressions, neurological disorders, Parkinson's disease, amyotrophic lateral sclerosis and Huntington's disease. In another aspect, this invention relates to a method of treatment in a subject having a gastrointestinal disease comprising functional bowel disorder. Other disease states alleviated by 5-HT6 agonists, and therefore by the compounds of Formula I, are gastrointestinal diseases comprising irritable bowel syndrome (IBS), and obesity.
In a preferred embodiment, the invention further relates to a process which comprises:
treatment of a compound of formula f
wherein P is a protective group and R
1
, R
2
and R
4
are as defined herein, with an arylsulfonyl halide of Formula Ar—SO2-Hal wherein Hal is a halogen; followed by deprotection to provide a compound of general Formula I:


REFERENCES:
patent: 5696122 (1997-12-01), Gaster et al.
patent: 6251893 (2001-06-01), Maddaford et al.
patent: 2002/0115670 (2002-08-01), Kelly et al.
patent: 2002/0165251 (2002-11-01), Caldirola et al.
patent: 19934433 (2001-01-01), None
patent: 0941994 (1999-09-01), None
patent: 60-190761 (1985-09-01), None
patent: WO96/03400 (1996-02-01), None
patent: WO98/27081 (1998-06-01), None
patent: WO01/32660 (2001-05-01), None
patent: WO 02/08178 (2002-01-01), None
patent: WO 02/32863 (2002-04-01), None
patent: WO 02/36562 (2002-05-01), None
patent: WO 02/41889 (2002-05-01), None
patent: WO 2002/041889 (2003-05-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.*
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.*
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.*
Robichaud, A.J. et al, Ann. Reports Med. Chem., vol. 35, 2000, 11-19.*
Kelley, Provisional Application 60/245,118, 2000.*
Caldirola, Provisional Application 60/243,115, 2000.*
Monsma, Jr. Frederick J., et al., “Cloning and Expression of a Novel Serotonin Receptor with High Affinity for Tricyclic Psychotropic Drugs,”Molecular Pharmacology, 1993, 43:320-327, The American Society for Pharmacology and Experimental Therapeutics.
Carlson, Rolf, et al., “Efficient Synthesis of Imines by a Modified Titanium Tetrachloride Procedure,”Acta Chemica Scandinavica, 1992, pp. 1211-1214, 46(12).
Matsumoto Masakatsu, et al., “A Facile Synthesis of 4-Oxo-4,5,6,7-Tetrahydroindoles,”Heterocycles, 1984, pp. 2313-2316, vol. 22, No. 10.

Affiliated with

Also associated with

Rating

4-piperazinylindole derivatives with 5-HT6 receptor affinity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 4-piperazinylindole derivatives with 5-HT6 receptor affinity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-piperazinylindole derivatives with 5-HT6 receptor affinity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3273548